The Discovery of Novel PGK1 Activators as Apoptotic Inhibiting and Neuroprotective Agents.

ABSTRACT: Stroke is the second leading cause of death worldwide and the leading cause of long-term disability that seriously endangers health and quality of human life. Tissue-type fibrinogen activator is currently the only drug approved by FDA for the treatment of ischemic stroke. Neuroprotection is theoretically a common strategy for the treatment of both ischemic and hemorrhagic stroke; therefore, the development of neuroprotective agent has been the focus of research. However, no ideal neuroprotective drug is clinically available. Phosphoglycerate kinase-1 (PGK1) activator has the effect of inhibiting apoptosis and protecting tissue damage, and therefore could be a potential neuroprotective agent. To obtain effective PGK1 activators, we virtually screened a large chemical database and their eval

SUBMITTER: Qiang SJ 

PROVIDER: S-EPMC8978560 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature